IDH2 and acute myeloid leukemia: Enasidenib was approved as monotherapy for R/R AML based on a phase 1/2 dose escalation and expansion study of 239 patients with IDH2-mutated AML, including 176 with R/R disease and 63 who were treatment naïve [80].